Abstracts Archive - Page 2159 of 2425 - ACR Meeting Abstracts

Abstract Number: 1357 • 2013 ACR/ARHP Annual Meeting
Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
T. Martijn Kuijper¹, Hong Xiong², A.E.a.M. Weel³, A.H. Gerards⁴, Jendé van Zeben⁵, P.H.P. de Jong⁶, Ilja Tchetverikov⁷, P.B.J. de Sonnaville⁸, M.V. Krugten⁹, B.A. Grillet¹⁰, Jolanda J. Luime² and Johanna M.W. Hazes¹¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁸Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ¹⁰Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: To explore the effect of psychosocial factors on the Disease Activity Score (DAS) and its components in early arthritis patients three months after initiating…
Abstract Number: 1358 • 2013 ACR/ARHP Annual Meeting
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Roy Fleischmann¹, Alan Kivitz², Ronald F van Vollenhoven³, James W. Shaw⁴, Stefan Florentinus⁵, Piyalal M. Karunaratne⁴, Hartmut Kupper⁶, Maxime Dougados⁷ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Methotrexate (MTX) in combination with the tumor necrosis factor inhibitor adalimumab (ADA) is an effective therapy for treating rheumatoid arthritis (RA), but the minimum…
Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Eimear Savage¹, David McCormick¹, Stephen McDonald¹, Michael Stevenson², Owen Moore³ and Andrew Cairns⁴, ¹Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, ²Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, ³Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁴Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…
Abstract Number: 1360 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients
Mélanie Rinaudo-Gaujous¹, Pierre Miossec², Vincent Blasco-Baque³, Philippe Gaudin⁴, Christian Genin¹, Thierry Thomas⁵, Stéphane Paul¹ and Hubert Marotte⁶, ¹Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ²Department of Clinical Immunology and Rheumatology, Immunogenomics and inflammation research unit, Lyon, France, ³Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵INSERM U1059 and University Hospital, Saint-Etienne, France, ⁶LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France
Background/Purpose: This study evaluates biological markers of rheumatoid arthritis (RA) severity including matrix metalloproteinase 3 (MMP-3) and Porphyromonas gingivalis (P. gingivalis) serology during infliximab therapy…
Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Mami Tamai^1,2, Yoshikazu Nakashima³, Junko Kita⁴, Ayuko Takatani⁴, Ayako Nishino³, Takahisa Suzuki³, Yoshiro Horai³, Akitomo Okada⁵, Shin-ya Kawashiri^3,6, Naoki Iwamoto³, Kunihiro Ichinose³, Kazuhiko Arima⁶, Hideki Nakamura³, Tomoki Origuchi⁷, Masataka Uetani⁸, Katsumi Eguchi⁹ and Atsushi Kawakami³, ¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ²Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…
Abstract Number: 1362 • 2013 ACR/ARHP Annual Meeting
Isymind Significantly Reduces MTX-Induced Nausea In a Pilot Trial
Eva Ostermeier¹, Hans Ulrich Koetter², Hans-Peter Tony³ and Ruth Pfister², ¹Rheumatology, University of Würzburg, Würzburg, Germany, ²iSyMind Institut, Giessen, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: MTX is the standard DMARD for treating rheumatoid arthritis and the most important partner for biological DMARDs. However MTX often induces heavy nausea accompanied…
Abstract Number: 1363 • 2013 ACR/ARHP Annual Meeting
Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study
Minkyung Kwon¹, Mindong Sung¹, Yong-Jin Kwon¹, Young Goo Song¹, Sang-Won Lee², Min-Chan Park¹, Yong-Beom Park¹, Soo-Kon Lee¹ and Jason Jungsik Song¹, ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea
Background/Purpose: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy and latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users.…
Abstract Number: 1364 • 2013 ACR/ARHP Annual Meeting
Detection of Latent Tuberculosis Infection in Rheumatologic Diseases Before Anti-TNFα Therapy: Tuberculin Skin Test Versus IFN-γ Assay
Suleyman Ozbek¹, Ismail Hanta², Sedat Kuleci³, Gulsah Seydaoglu³ and Ezgi Ozyilmaz³, ¹Division of Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, ²Pulmonary, Cukurova University, Adana, Turkey, ³Cukurova University, Adana, Turkey
Background/Purpose: We aimed to evaluate tuberculin skin test (TST) and interferon-gamma (IFN-γ) test results for latent tuberculosis infection (LTBI) in patients with rheumatologic diseases prior…
Abstract Number: 1365 • 2013 ACR/ARHP Annual Meeting
Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Jun Nakamura¹, Takao Nagashima¹, Katsuya Nagatani², Taku Yoshio³, Masahiro Iwamoto⁴ and Seiji Minota⁵, ¹Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ³Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ⁴Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, ⁵The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still…
Abstract Number: 1366 • 2013 ACR/ARHP Annual Meeting
Abdominal Adiposity and Body Composition In Rheumatoid Arthritis: Relation With Disease Characteristics In A Case-Control Study
Ivan Ferraz-Amaro¹, Esmeralda Delgado-Frías², Vanesa Hernandez-Hernandez³, Jose Ramon Muñiz⁴, Antonieta Gonzalez-Diaz⁵, Angeles Gomez Rodriguez-Bethencourt⁵ and Federico Diaz-Gonzalez⁶, ¹Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ²Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ³Rheumatology, Rheumatology Service, Santa Cruz de Tenerife, Spain, ⁴Resonancia Magnética IMETISA, Resonancia Magnetica IMETISA, Santa Cruz de Tenerife, Spain, ⁵Servicio de Medicina Nuclear, Santa Cruz de Tenerife, Spain, ⁶University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: To determine the relationship between measures of body composition (total body composition derived from dual energy X-ray absorptiometry and abdominal adiposity through magnetic resonance…
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 1368 • 2013 ACR/ARHP Annual Meeting
The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis
Faye A H Cooles¹, Arthur G Pratt^2,3,4, Wan-Fai Ng^3,5, Terry J Aspray³ and John D Isaacs², ¹Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom
Background/Purpose: There is increasing evidence that vitamin D has immunoregulatory properties in autoimmunity. In established rheumatoid arthritis (RA) there appears to be an inverse association…
Abstract Number: 1369 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease
Mélanie Rinaudo-Gaujous¹, Adeline Moreau¹, Vincent Blasco-Baque², Xavier Roblin³, Christian Genin¹, Thierry Thomas⁴, Stéphane Paul¹ and Hubert Marotte⁵, ¹Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ²Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, ³Department of gastroenterology, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France, ⁵INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France
Background/Purpose: Periodontal disease (PD) is associated mainly with rheumatoid arthritis (RA), but recent data suggest an association with ankylosing spondylitis (AS). Role of Porphyromonas gingivalis…
Abstract Number: 1370 • 2013 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases
Wieneke van den Hombergh¹, Annelies van Ede², J. Fransen³, Femke BG lamers-Karnebeek³, Saskia Kuipers⁴ and Matthijs Janssen⁵, ¹Rheumatology, UMC st. Radboud, Nijmegen, Netherlands, ²Rheumatology, UMC st Radboud, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Microbiology, UMC st Radboud, Nijmegen, Netherlands, ⁵Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands
Background/Purpose: Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromized hosts. Prednisone is frequently suggested as a risk factor for developing pneumocystis pneumonia (PCP) in patients with rheumatic diseases. If prednisone…
Abstract Number: 1371 • 2013 ACR/ARHP Annual Meeting
Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Jong Wook Beom¹, Eun-Jung Park², Jinseok Kim³, Se Chang Park⁴ and Gi Hyeon Seo⁵, ¹Medicine, Jeju National University Hospital, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Veterinary Medicine, Seoul National University, Seoul, South Korea, ⁵Health Insurance Review and Assessment Service, Seoul, South Korea
Background/Purpose: Tumor necrosis factor-α (TNF-α) antagonists bring new hope for treating rheumatoid arthritis (RA) over the past decade. However, the subsequent increased risk of developing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].